Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04573153|
Recruitment Status : Unknown
Verified September 2020 by ScandiBio Therapeutics AB.
Recruitment status was: Recruiting
First Posted : October 5, 2020
Last Update Posted : October 6, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|COVID-19||Drug: Hydroxychloroquine + Metabolic cofactor supplementation Drug: Hydroxychloroquine + Sorbitol||Phase 2 Phase 3|
Coronaviruses are a large family of ribonucleic acid viruses that cause mild to moderate upper respiratory diseases in humans. There is an urgent need for COVID-19 therapeutics due to the S-shaped curve expansion of the infections, widespread pandemic status, and global burden. Given the similarities between SARS-CoV-2 and other coronaviruses, and its relative ease of sample acquisition and study, it has been widely accepted that drug repositioning is a promising approach to make available an effective, safety-assured treatment in a timely manner.
This open label, randomized, controlled, investigator-initiated, multi-centre trial aims to establish metabolic improvements in COVID-19 subjects by dietary supplementation with cofactors N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside and serine plus standard therapy. The investigational drug products, the mixture of the four co-factors will be administered as a powder with strawberry aroma to be dissolved in 200 ml of preferably cold still drinking water and be consumed within 5 minutes.
This study is planned as a Phase II / III clinical drug research to be conducted in patients diagnosed with COVID-19. Patients will be ambulatory and after the diagnosis/confirmation of diagnosis, will be sent home with their treatment. However, patients may be hospitalised during this initial examination period due to deterioration in their physical health or due to any medical condition which was not present at admission.
The primary objective is to assess the clinical efficacy of the combination of metabolic cofactors supplementation and hydroxychloroquine in COVID-19 patients. For the primary purpose, the proportion of patients who were hospitalised during the course of disease until 14 days after the initial diagnosis of Covid-19 disease will be compared. Patients who were hospitalised during the 14-day period, but at any time point after consenting will be evaluated as an end-point occurrence.
The secondary aim in this study is to evaluate the safety and tolerability of metabolic cofactors supplementation and hydroxychloroquine combination.
The initial part of the Phase II/III study is planned as a Phase II study which will enrol 100 patients and after an interim analysis it will conclude as a Phase III study (300 patients). Totally 400 COVID-19 disease patients will be randomized on a 3:1 basis to the combination metabolic cofactors supplementation and hydroxychloroquine or hydroxychloroquine+ placebo in eight clinical sites in Turkey.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||400 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||This study was planned as a parallel group, randomized and open label study. The subjects will be randomized on a 3:1 basis to the cofactor supplementation combination plus hydroxychloroquine treatment or hydroxychloroquine +placebo treatment.|
|Masking:||None (Open Label)|
|Official Title:||A Multi Centre, Randomised, Controlled, Open-Label Phase 2/3 Study to Evaluate The Efficacy, Tolerability and Safety of Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients|
|Actual Study Start Date :||September 21, 2020|
|Estimated Primary Completion Date :||January 31, 2021|
|Estimated Study Completion Date :||March 31, 2021|
Experimental: Treatment Arm
Subjects in ambulatory-at home-treatment will receive hydroxychloroquine (standard therapy) + dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.
Drug: Hydroxychloroquine + Metabolic cofactor supplementation
Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).
Placebo Comparator: Placebo Arm
Subjects will take hydroxychloroquine (standard therapy) + dietary supplement placebo.
Drug: Hydroxychloroquine + Sorbitol
Placebo comparator will include sorbitol as placebo + standard therapy (hydroxychloroquine).
- The evaluation of clinical efficacy of the combination of metabolic cofactor supplementation and hydroxychloroquine [ Time Frame: 14 days ]The clinical efficacy will be evaluated by comparing the proportion of patients who were hospitalised during the course of disease until 14 days after the initial diagnosis of Covid-19.
- Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment [ Time Frame: 14 days ]Number/characteristics of Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment due to study drug from baseline until the end of study.
- Chest Tomography [ Time Frame: 1 day ]Chest imaging will be documented at baseline visit.
- ECG Measurement [ Time Frame: 1 day ]Change in heart rate will be measured at baseline visit.
- Change of complete blood count from baseline [ Time Frame: 14 days ]Complete blood count includes number of blood cells and concentration of hemoglobin. Complete blood count will be performed to measure possible toxic effects of the metabolic cofactors supplementation and hydroxychloroquine combination on hematological system.
- Changes in alanine aminotransferase (ALT) levels from baseline [ Time Frame: 14 days ]Clinical evaluation of ALT levels from baseline until the end of study.
- Changes in aspartate aminotransferase (AST) levels from baseline [ Time Frame: 14 days ]Clinical evaluation of AST levels from baseline until the end of study.
- Changes in C-reactive protein (CRP) levels from baseline [ Time Frame: 14 days ]Clinical evaluation of CRP levels from baseline until the end of study.
- Changes in creatinine levels from baseline [ Time Frame: 14 days ]Clinical evaluation of creatinine levels from baseline until the end of study.
- Changes in D-dimer levels from baseline [ Time Frame: 14 days ]Clinical evaluation of D-dimer levels from baseline until the end of study.
- Changes in ferritin levels from baseline [ Time Frame: 14 days ]Clinical evaluation of ferritin levels from baseline until the end of study.
- Changes in triglycerides levels from baseline [ Time Frame: 14 days ]Clinical evaluation of triglycerides levels from baseline until the end of study.
- Changes in LDH levels from baseline [ Time Frame: 14 days ]Clinical evaluation of LDH levels from baseline until the end of study.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Patients of both genders (females and males) over 18 years of age
- Written informed consent obtained from the subjects prior to any procedures related to the study
- Understand all procedures to be applied within the scope of the study protocol
- Ambulatory patients with symptoms diagnosed with COVID-19 with Chest tomography (CT) result positivity in the last 72 hours
- Patients with stable clinical course and who could be treated on an ambulatory basis.
- Patients who has partial oxygen saturation below 93% and require immediate hospitalisation after diagnosis
- Patients, upon initial examination, decided to be hospitalised at the intensive care-unit
- Inability or unwillingness to give written informed consent
- At physicians decision, the trial involvement will not be in patients' best interest, or any condition that does not allow the protocol to be followed safely
- Patients considered as inappropriate for this study for any reason
- Active participation in another clinical study
- Uncontrolled Type 1 or type 2 diabetes
- Severe liver disease (e.g. Child Pugh score ≥ C, AST>5 times upper limit)
- Patients with known severe renal impairment (estimated glomerular filtration rate ≤30 mL/min/1.73 m2) or receiving continuous renal replacement therapy, hemodialysis, peritoneal dialysis
- Significant cardiovascular co-morbidity (i.e. heart failure)
- Patients with phenylketonuria (contraindicated for NAC)
- Known allergy for substances used in the study
- Pregnant or breastfeeding patients, or patients with positive pregnancy test in a pre-dose examination
- Receipt of any experimental treatment for COVID-19 within the 30 days prior to the time of the screening evaluation.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04573153
|Contact: Assoc. Prof. Levent DOĞANAY, MD||+90 505 525 04 email@example.com|
|University of Health Sciences Istanbul Ümraniye Training and Research Hospital||Recruiting|
|Contact: Assoc. Prof. Levent DOĞANAY, MD +90 505 525 04 91 firstname.lastname@example.org|
|Principal Investigator:||Assoc. Prof. Levent DOĞANAY, MD||University of Health Sciences Istanbul Ümraniye Training and Research Hospital|
|Responsible Party:||ScandiBio Therapeutics AB|
|Other Study ID Numbers:||
|First Posted:||October 5, 2020 Key Record Dates|
|Last Update Posted:||October 6, 2020|
|Last Verified:||September 2020|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Respiratory Tract Infections
RNA Virus Infections
Respiratory Tract Diseases
Molecular Mechanisms of Pharmacological Action